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Treatment in the STAMPEDE era for
castrate resistant prostate cancer in the UK:
ongoing challenges and underappreciated
clinical problems
Rosa U. Greasley1, Rebecca Turner2, Karen Collins3, Janet Brown4, Liam Bourke1*† and Derek J. Rosario2†
Abstract
Background: This study aimed to explore the opinions of healthcare professionals regarding the management of
men with advanced prostate cancer with particular emphasis on treatment timing and sequencing; treatment
adverse-effects and exercise a supportive therapy.
Methods: Semi-structured interviews with a purposively selected group of healthcare professionals involved in
prostate cancer care within the NHS, conducted over the phone or face to face. A total of 37 healthcare professionals
participated in the interviews including urologists, clinical oncologists, medical oncologists, clinical nurse
specialists, general practitioners, physiotherapists, exercise specialists, service managers, clinical commissioners
and primary care physicians.
Results: The availability of newer treatments for advanced prostate cancer as well as results from the STAMPEDE and
CHAARTED trials has resulted in new challenges for patients and HCPs. This includes the impact of an increased workload
on oncologists, a potential lack of clinical continuity between urology and oncology and uncertainties regarding optimal
selection, timing and sequencing of chemotherapy and second-line treatment. Fitness for treatment in advanced prostate
cancer populations remains a significant barrier to accessing therapies for patients with a poor performance
status. Among this, muscle wastage can significantly affect performance status and consequentially compromise
cancer therapy. Exercise was regarded as a potential therapy to mitigate the adverse-effects of treatment
including the prevention or reduction in muscle wastage.
Conclusions: There is a lack of data guiding clinicians in this post STAMPEDE and CHAARTED era, work is needed to
reassess and optimize the prostate cancer care pathway as it evolves. Exercise should be explored as a therapeutic
option to mitigate the effects of long term ADT. Further study from a wider cohort of both prostate cancer care
specialists and patients will aid in establishing a highly functioning pathway with optimal individualised care.
Trial registration: Sustained exercise TrAining for Men wIth prostate caNcer on Androgen deprivation: the STAMINA
programme (RP-DG-1213-10,010). REC Reference: 15/SW/0260 IRAS Project ID: 178340 Hospital ID: STH 18391 approved
on 24/08/2015.
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Background
Until 2010, docetaxel chemotherapy remained the only
therapy for castrate resistant prostate cancer (CRPC) which
demonstrated a significant survival benefit (18.9 months vs
16.5 months in the docetaxel groups vs mitoxantrone
group) [1, 2]. Post 2010, there has been an introduction of
five other therapeutic options which have also shown a
survival benefit in phase III trials: cabazitaxel, sipuleucel-T,
radium-223, abiraterone and enzalutamide [3–8]. Improve-
ments in survival of men with the use of docetaxel at
earlier (hormone sensitive) stages of metastatic (M1)
prostate cancer have been demonstrated in the recent
multicentre randomized controlled trials STAMPEDE and
CHAARTED [9–11] .The introduction of docetaxel upon
initiation of androgen deprivation therapy (ADT) had a
significant survival benefit when compared to the ADT
group alone in hormone-sensitive M1 disease (57.6 vs
44.0 months, 95% CI 0.47 to 0.81; P < 0.001) [9]. Conse-
quentially, in 2015 changes in clinical practice followed
and an increasing number of men will receive chemother-
apy earlier in their prostate cancer care pathway.
This rapid growth in treatment options since 2010 and
the uncertainty around the efficacy of newer agents in
the post-docetaxel setting (due to earlier exposure to
docetaxel) presents oncologists and urologists with
issues concerning the optimal sequencing and adherence
to subsequent treatment regimens as well as potential
adverse-effects of cytotoxic agents and the impact on
quality of life (QoL) [12].
Additionally, in the UK, urologists do not prescribe
taxane-based chemotherapeutics for prostate cancer,
and the optimal referral route between urology and
oncology is variable between National Health Service
(NHS) trusts. Establishing coherent and optimised care
pathways not only offers obvious benefits for impact-
ing treatment outcomes, but also creates a culture of
ownership, responsibility and accountability within the
clinical team [13].
There are unappreciated emerging needs common to
advanced cancer patients which are not being adequately
addressed in uro-oncology. The adverse-effects of long
term ADT need to be explored to aid clinicians in
treatment based decision making and direct research
with an aim to reduce those effects that have the
biggest detriment on the health and wellbeing of
these men. This includes the loss of lean body mass
(LBM) which can significantly impact on response to
chemotherapy and fitness for treatment, but is still
largely unappreciated in clinic [14–16]. Cancer pa-
tients of lower performance status (PS) and a LBM
have repeatedly been shown to have more dose
limiting toxicity, a poorer chemotherapy completion
rate, a higher risk of neutropenia and poorer overall
survival (OS) [17–20].
Complimentary interventions such as exercise pro-
grammes aimed to improve outcomes for men on long
term ADT are well documented, however robust data
surrounding that for men with CRPC is lacking [21, 22].
Exercise presents as a potential effective treatment to aid
in mitigating the effects of long term ADT which may
be of specific benefit to this group of men, improving
prostate cancer specific outcomes and LBM [22–24].
Methods
The aim of this qualitative study was to explore the
views and opinions of specialist health care profes-
sionals (HCPs) within the UK regarding prostate can-
cer care pathway organisation, sequencing of treatment
(including fitness for treatment), the adverse-effects of
treatment for men with CRPC and exercise for men
with CRPC.
From December 2015 to May 2016 qualitative
semi-structured interviews were undertaken with a
purposively selected group of HCPs (see Table 1)
responsible for prostate cancer management. HCPs were
identified through national prostate cancer care teams
based in the NHS or professional bodies. Seventy-eight
HCPs in total were approached, and those who expressed
interest (n = 49) were sent an invitation letter, participant
information sheet and consent form via post. Once
consent was obtained, dates for interview were confirmed
via email or a telephone call. The interviews were digitally
recorded and then anonymised. After transcription, the
data were coded via Nvivo10 and analysed according to a
thematic framework analysis [25].
Table 1 HCP demographics of those interviewed
Country of service England 100% (37)
Profession Consultant Urologist 24.3% (9)
Clinical Oncologist 18.9% (7)
Medical Oncologist 8.1% (3)
Clinical Nurse Specialist 16.2% (6)
General Practitioner 8.1% (3)
Physiotherapist 8.1% (3)
Exercise Specialist 5.4% (2)
Service Manager 2.7% (1)
Clinical Commissioner 8.1% (3)
Primary Care Physician 2.7% (1)
Institution Teaching Hospital 24.3% (9)
District Hospital 18.9% (7)
University 2.7% (1)
Community 13.5% (5)
Cancer centre 29.7% (11)
Primary Care 10.8% (4)
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Details on the interview schedule are provided in the ap-
pendix (Additional file 1). Thematic framework analysis
was chosen as it was the most pragmatic approach to sys-
tematically facilitate rigorous and transparent data man-
agement without losing sight of the “raw data” and
enabled the classification of the data into key themes and
sub themes, judged comprehensively. This 6 step ap-
proach included familiarising with the data; generating ini-
tial codes; searching for themes; reviewing themes;
devising and naming themes and producing the report
[26]. This research was conducted following the guidelines
for standards for reporting, process and methods from the
COREQ criteria [27]. A second researcher was used to
double code the interviews. A case and theme based
approach was used to develop the qualitative framework.
The study protocol, topic guides and semi-structured
interview schedules gained national NHS ethics approval
by NRES Committee South West - Cornwall & Plymouth
(15/SW/0260) and in accordance with the Governance
Arrangements for Research Ethics Committees and
complies fully with the Standard Operating Procedures for
Research Ethics Committees in the UK. All Management
permissions were sought from all NHS organisations
involved in the study in accordance with NHS research
governance arrangements. All participants gave written
informed consent before participation in this study.
Sustained exercise TrAining for Men wIth prostate
caNcer on Androgen deprivation: the STAMINA
programme (RP-DG-1213-10,010). REC Reference: 15/
SW/0260 IRAS Project ID: 178340 Hospital ID: STH
18391 approved on 24/08/2015.
Results
Thirty-seven interviews with HCPs were undertaken,
their demographics detailed in Table 1. Seven inter-
views were undertaken face to face and thirty over the
telephone. Four themes were identified from the data.
Verbatim quotes are provided in Table 2 to illustrate
the findings.
Theme 1: The prostate cancer care pathway:
continuity of care.
Stampede and Chaarted
The urologists and oncologists involved in secondary care
stated that the recent data from the STAMPEDE and
CHAARTED trials had changed the prostate cancer path-
way resulting in men with advanced hormone-sensitive
disease being offered chemotherapy alongside initiation of
first line ADT [9, 11]. Oncologists stated that they were
facing increasing numbers of referrals of men with
hormone sensitive disease and therefore had a greater role
in the care pathway than prior to the pathway change,
where predominantly they had treated men with CRPC.
The majority felt this presented an increased workload for
oncologists and potential problems that NICE or the NHS
may have not foreseen, consequentially yielding further
uncertainty.
Changes to standard care
In light of the changes brought upon by STAMPEDE
and CHAARTED, the pressure to change practice was
felt to have put additional strain on the cross-over of
patient care from urology to oncology as it ensues earlier
now docetaxel is offered at hormone sensitive stages. A
medical oncologist talked specifically about the time
constraints surrounding the simultaneous initiation of
chemotherapy and ADT. The current recommendations
(based on the trial data) state that docetaxel should be
initiated within 90 days of starting ADT [28].
“[…] That has caused a problem, at an MDT,
yesterday because they referred a patient who was five
months out […] and then the patient got upset that
they weren’t offered it [docetaxel with ADT] [...] But
then there’s no evidence for it, [beyond] 90 days.”
(Medical Oncologist).
Theme 2: Uncertainty with treatment sequencing
in CRPC
Treatment sequencing
The majority of the oncologists and urologists felt that
changes to the prostate cancer care pathway had resulted
in dilemmas associated with the sequencing of treatment.
Prior to the STAMPEDE and CHAARTED data, men with
newly diagnosed CRPC would be chemo-naïve (i.e. no
previous docetaxel regimen given). It was obvious amongst
these HCPs that the standard of care would change for
men with CRPC given that these men are likely to have
had docetaxel earlier in the care pathway. Thirty-seven
interviews with HCPs. 1 describes the current sequencing
of docetaxel in the STAMPEDE and CHAARTED era.
“[…] I think if somebody’s had adjuvant chemotherapy
when they relapse I would be more inclined to go to
further hormone therapies first before going back to
chemotherapy. Mm, I haven’t decided about that yet.”
(Medical Oncologist).
Performance status, fitness for treatment and treatment
decisions
There were some conflicting statements regarding sequen-
cing second line ADT (enzalutamide and abiraterone) and
chemotherapy for men with CRPC. Some of the inter-
viewees alluded to patients having to have a better PS to
receive second line ADT particularly pre-chemotherapy.
Other HCPs stated that men would generally have to have
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a better PS, or be fitter, for them to consider chemotherapy
before second line ADT or at any stage.
Theme 3: Quality of life and adverse-effects.
Physiological adverse-effects of treatment
Generally, adverse-effects which were commonly men-
tioned to be associated with ADT were fatigue, weight
gain, hot flushes, muscle weakness/ wastage (particularly
worse when compounded with steroids), a decrease in
sex drive and breast swelling (gynecomastia). Those
most commonly mentioned with chemotherapy were
neutropenia (with a chronic worry of acute death),
emesis (vomiting), peripheral neuropathy and fatigue.
Impact on quality of life
The physiological effects of ADT were recognised as
having a profound effect on QoL, impacting on the abil-
ity to work, social life and interpersonal relationships. In
Table 2 Verbatim quotes and their corresponding themes
Theme 1: The prostate cancer pathway: continuity of care
STAMPEDE and CHAARTED
“Before NHS agreed to fund it [docetaxel for men with metastatic hormone
sensitive disease] in January, we were just doing it based on the American
study [CHAARTED], which was the more extensive group [higher volume
metastatic disease] and not do the people with minimal disease. And we’re
trying to still do that, just to keep the numbers down...I’m in the process of
being made to say that we’re going to have to have a waiting list for
these patients.” (Medical Oncologist)
Changes to standard of care
“…That has caused a problem, at an MDT, yesterday because they referred
a patient who was five months out…and then the patient got upset that
they weren’t offered it [docetaxel with ADT]...But then there’s no evidence
for it, beyond 90 days…surgeons would argue that if there’s no evidence
you should give. Whereas oncologists argue that if there’s no evidence you
shouldn’t give [docetaxel].” (Medical Oncologist)
Theme 2: Uncertainty with treatment sequencing in CRPC
Treatment sequencing
“Yes, it always has changed practice. So basically all patients who are of
shall I say good performance status, have limited comorbidity are now
being considered for chemotherapy alongside androgen deprivation
therapy for metastatic hormone sensitive disease…So a lot of it [treatment
options] is individual…[future treatment] will change somewhat because
the use of chemotherapy may have happened earlier on for hormone
sensitive disease.” (Clinical Oncologist)
“But I think I probably would still go for, let’s see, I think if somebody’s had
adjuvant chemotherapy when they relapse I would be more inclined to go
to further hormone therapies first before going back to chemotherapy. Mm,
I haven’t decided about that yet.” (Medical Oncologist)
Performance status, fitness for treatment and treatment decisions
“…to get enzalutamide or abiraterone [men with CRPC] have to be
performance status zero or one. And they have to have, be asymptomatic
or minimally symptomatic…So you can’t give it to patients who are poorly
or you shouldn’t give it to patients who are poorly…Well actually the
docetaxel performance status is zero to two. So if you have a poorly
patient and some people will, if they have say liver mets or what have you,
they’ll go straight to docetaxel…I would, if I had someone who was really
fit, I would potentially give them enzalutamide or abiraterone pre-
chemotherapy, if they had liver or lung involvement.” (Medical Oncologist)
“…although in young fit men that probably will influence me giving
docetaxel before giving abiraterone, yes, or enzalutamide…so performance
status, they’d have to be PS 0 or 1 for me to give them docetaxel
generally,with good renal function, and you know, just generally a good
performance status” (Clinical Oncologist)
“So you can be fairly unfit to have hormones, but for the chemotherapy
we’d only offer that to people who are fit basically…at some level, able to
withstand it anyway.” (Urologist)
Theme 3: Quality of Life and adverse effects
Physiological adverse-effects
“These things go off a bit of a cliff when they start the hormone therapy,
so they’ve got a sense of what they’re normally like, and they very quickly
get a sense that they’re different on hormones.” (GP)
“Fatigue, hot flushes, hot flushes are probably the top one, a change in
mood...I often see men for urinary urgency and frequency.”
(Physiotherapist)
Compromising treatment and muscle wastage
“Well, I think the benefits have to be twofold, don’t they, so there are
disease specific benefits and then there’s QoL and they’re not necessarily
aligned.” (Urologist)
“…really quality of life is a, it’s a huge issue and there’s no point in keeping
people alive if we’re wrecking their lives.” (Clinical Oncologist)
Table 2 Verbatim quotes and their corresponding themes
(Continued)
“So I’ve seen muscle wasting that was quite significant that was stopping
somebody from going out and doing their job…So, although there was
data for overall survival benefit in continuing the hormones, I stopped the
hormones after discussion, because I felt that we’re going to leave him
housebound…” (Clinical Oncologist)
“While I don’t have any method in clinic of assessing muscle wastage and I
certainly don’t have time to sit measuring their muscle bulk...I probably
should weigh them more often, but it depends what I’m going to do about
it, I guess.” (Clinical Oncologist)
Theme 4: Prostate cancer and exercise
NICE recommendations and purpose
“Well I was surprised to find out that NICE’s has actually made
recommendations and usually when NICE makes a recommendation then
it, it eventually happens because it means it’s going to be funded.” (Clinical
Oncologist)
“I personally think it’s a fundamental aspect of healthcare so, you know, I
think it would be hugely beneficial if we had more access to it.” (GP)
“if it was a drug, exercise would be being prescribed all the time ...” (GP)
Physiological and psychological benefits. “Well I think there’s increasing
evidence that exercise decreases death rate, not just prostate cancer but
cardiovascular fitness and cancer, you know there is a link…
So your chances of survival and good quality of life increase massively if
you’ve got a normal body mass index and you’ve got cardiovascular
fitness...” (GP)
“I think an increased feeling of well-being, an increased quality of life,
reduction in cardiovascular morbidity and mortality.” (Urologist)
Management of adverse effects
“…to sort of masculate them a little bit more by sort of encouraging them
with exercise...and seeing the feedback that they give at the end is great
really, and it’s giving them control because, you know, it’s quite a man-
thing isn’t it, sort of needing to be in control a little bit more.”
(Physiotherapist)
“I think it’s beneficial for maintaining muscle strength, quality of life and
exercise capacity, which I think is very important for them, and it keeps
some bone strength, you know, when on their long-term hormones, the
more exercise they do the more they can maintain their bone strength,
which is going to be a good thing, And it’s good psychologically, you
know, if they can keep going out and playing golf or doing whatever they
do, then I think that’s very important for them.” (Clinical Oncologist)
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particular, effects on physical function which impaired
the ability of these men to work were considered se-
verely detrimental to QoL.
Compromising treatment and muscle wastage
Determining the root cause of an adverse-effect is funda-
mental to maintaining a patient’s QoL whilst succeeding
with the best possible treatment regimen to control
disease. Dropping the dose, treatment breaks or switch-
ing to an alternate therapy can be an option if a man’s
experience is such that the clinician regards this to be
necessary.
Changes to treatment regimens were deemed neces-
sary for some HCPs where muscle wastage becomes a
problem in a patient. One example given by a clinical
oncologist described how ADT was stopped due to ex-
treme muscle wastage in one patient.
HCPs were asked if muscle wasting could be
identified as a result of anti-neoplastic treatment
(ADT/steroids) or the disease process (cancer cach-
exia). A majority felt they could adequately assess this
based on a subjective assessment of the patient (by
eye) and by noting any marked deterioration in PS or
wellbeing over a period of time. HCPs were unani-
mous that currently there exists no robust diagnostic
procedure when distinguishing muscle wastage of
different aetiologies.
Theme 4: Prostate cancer and exercise.
NICE recommendations and purpose
Almost all the HCPs seemed to have knowledge of the
NICE recommendations for exercise in men with pros-
tate cancer (section 1.4.19 in CG175). However, there
was some confusion as to why, given that NICE has
made the recommendations, action had not been taken
nationally to implement them.
“if it was a drug, exercise would be being prescribed
all the time [ ...]” (GP).
Most HCPs felt that an exercise programme had a
place within healthcare, as there was perceived benefit
and purpose of exercise programmes.
Physiological and psychological benefits
Supervised exercise was viewed as having many benefits
men with prostate cancer, physically and psychologically.
The HCPs specifically spoke about improvements in car-
diovascular health, reducing BMI, increasing muscle
mass and decreasing mortality. Beneficial effects to QoL
included improvements in social life, the ability work
and complete activities of daily living.
Management of adverse-effects
Some of the HCPs saw exercise as a way to manage the
adverse-effects of cancer therapies and means for these
men to take back some control over their health.
The physiological benefits commonly mentioned by
the interviewees were the maintenance of muscle bulk
and bone health, which is often compromised on ADT,
and the increased tolerance of treatment and a reduction
in complications (surgical or medicinal).
Discussion
This qualitative study of 37 HCPs in the UK has
highlighted a lack of continuity in the prostate cancer
care pathway between urologists and oncologists and the
increased workload on oncologists posed by earlier
introduction of newer systemic therapies presents new
challenges in optimum care for men with prostate
cancer. Furthermore, uncertainty exists around optimal
selection, timing and sequencing of chemotherapy and
second-line treatment amongst the HCPs.
The trials which assessed the use of abiraterone and
enzalutamide for men with CRPC were predominantly in
men with good PS (Eastern Cooperative Oncology Group,
ECOG 0–1) [5, 8, 29–31]. For the minority of men in
these trials with a poorer PS (ECOG ≥2) no significant OS
benefit was demonstrated with either abiraterone or enza-
lutamide. For this reason NICE recommends the use of
these drugs in men with CRPC with no or mild symptoms.
In the post-docetaxel setting abiraterone is only recom-
mended in men whose disease has progressed on or after
one docetaxel-containing chemotherapy regimen. NICE
recommends use of enzalutamide in a pre-docetaxel
setting or post one course of docetaxel-containing regi-
men in men with no or mild symptoms (PS 0–1).
The recently published LATITUDE and STAMPEDE
trial data has demonstrated an OS benefit and
radiographic-progression free survival benefit of abira-
terone and prednisolone alongside ADT in men in men
with newly diagnosed, metastatic hormone sensitive
prostate cancer and men initiating long term ADT [32,
33]. It is likely that abiraterone will therefore shift to
earlier use in the prostate cancer pathway, similar to the
shift seen with docetaxel. There may be further uncer-
tainty surrounding optimum therapy sequencing, and
neither study assessed the initiation of ADT plus abirater-
one alongside docetaxel or versus ADT plus docetaxel, so
there lacks comparative data for the new standard of care.
Therefore for those with a poorer PS, the need for robust
data around the efficacy of subsequent treatments after
progression becomes crucial.
Docetaxel is a widely used drug, relatively inexpensive
and a common therapy used for CRPC. Conceptually,
the move to earlier administration in the care pathway
men presenting with metastatic disease simultaneous
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with initiation of long term ADT following publication
of the CHAARTED and STAMPEDE studies [9–11] has
been relatively easy. Nevertheless, it is recognised that
whilst the implementation of docetaxel earlier is both
recommended and feasible, there are implications on the
care pathway and resource utilisation [34] with add-
itional workload for oncologists and increased demand
on oncology units. Discontinuity between urology and
oncology might risk delayed referral and compromise the
treatment which can be offered to a man; treatment which
he should be eligible for. As described by the medical
oncologist (see “Stampede and Chaarted” Table 2) this has
arguably risked sub-optimal care by restricting the num-
bers of men referred for chemotherapy.
Figures from the Royal College of Radiology report
estimates that 67 full-time oncology consultants are
required immediately to cover the current excess of
clinical workload in the NHS and nearly 1 in 5 could
retire from the workforce in the next 5 years [35]. With
an ever-growing cancer population which is surviving
longer yet a lack of oncology work force to meet the
required demands on the cancer services, the NHS is
facing a potential crisis [35].
In addition to the immediate strain brought on by the
change in the prostate cancer care pathway, it is import-
ant to consider how the introduction of docetaxel earlier
will affect subsequent treatment sequencing at CRPC
stages (Fig. 1). There was a lack of clarity in how doce-
taxel and second generation anti-androgens, abiraterone
and enzalutamide, may be sequenced for men in the
post-STAMPEDE era. Including how decisions would be
made to give further docetaxel chemotherapy regimens,
if men have previously received docetaxel, and how
effective a second docetaxel regimen may be further
Fig. 1 The post-STAMPEDE and CHAARTED data prostate cancer care pathway. The blue boxes represent the localised and locally advanced prostate
cancer care pathway in brief. The red boxes represent the advanced prostate cancer care pathway leading to castrate resistance and the therapeutic
options at this stage of disease. Steroids such as prednisone are also given as standard care alongside these drugs. The green boxes show docetaxel,
now offered upon the initiation of ADT (within 90 days) at newly diagnosed hormone sensitive advanced metastatic disease (M1). This has caused
uncertainty in the sequencing of treatments as the disease advances to CRPC as well as the efficacy of these drugs now men have already undergone
one docetaxel regimen and are no longer “chemo-naive”. It is also unclear how a second potential docetaxel regimen would be sequenced
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down the line. Some of the HCPs commented that
second generation anti-androgens, would be offered in
the place of chemotherapy where it is felt the man may
not tolerate docetaxel due to a poorer PS.
With a lack of trial data, clinical guidance and clarity
surrounding treatment sequencing, treating clinicians
face a major dilemma. They may have to make a treat-
ment evaluation on a patient and potentially offer un-
suitable treatments based on the premise that there is
no suitable alternative. Furthermore, the optimum pre-
or post-docetaxel therapy is heavily debatable in CRPC
given that there is no suitable comparison data, forcing
clinicians to make decisions based on assumptions and
clinical experience rather than true “level one” data.
Based on the findings from the interviews, some clini-
cians seem to be treating patients with poorer PS’ with
abiraterone preferentially over chemotherapy whilst
there lacks available data as to whether it may actually
improve survival. Contraindications to docetaxel use are
a poor PS (ECOG 3–4, caution for those with PS 2) [36].
This gives such men even fewer treatment options, given
that NICE does not recommend the use of second
generation anti-androgens. With these limitations, we
can conclude that fitness is a key aspect in treatment
decision making by clinicians and improving or main-
taining a man’s PS to 0–1 enables access to the neces-
sary therapies and ensures the best possible outcomes.
Fitness for treatment is a predominant factor in a cli-
nician’s treatment based decision [37] and in advanced
cancer populations remains a significant barrier for ac-
cess to the available therapies in patients with a poor PS.
Physiological adverse-effects of ADT such as fatigue,
muscle wasting and increased central adiposity, which
can significantly impact on QoL, can also compromise
eligibility for treatment, where it interferes with per-
formance status.
The shift in treatment paradigms to move docetaxel
earlier in the care pathway comprises of both positive
effects and a degree of uncertainty when fitness for
treatment is considered. On one hand, men receiving
docetaxel at hormone sensitive stages will likely be on
average younger and have a better PS when compared to
the castrate resistant setting. The combination of doce-
taxel with ADT at hormone sensitive stages has also
been shown to significantly increase progression free
survival meaning these men enter the castrate resistant
phase of the disease later [38]. These men are therefore,
at this stage, not only likely to tolerate the docetaxel
better, maintaining the optimum drug dosage, but pro-
long the time to which they will need further therapy for
advancing disease. On the other hand, when men do
eventually progress to CRPC, the long term effects of a
previous docetaxel regimen on PS and fitness for treat-
ment are unclear. This may also be compounded by the
adverse-effects of long term ADT given that these men
can remain on first line ADT for many years.
Treatment evaluation of a patient with CRPC is
pertinent given the predominance of muscle wasting and
deterioration in bone health [39]. The effects of muscle
wastage appear to have significant implications on the
fitness and PS of a man, and therefore not only impact-
ing his current therapy but also likely to affect the future
treatments offered as his disease progresses. Retrospect-
ive data has associated better OS in men with metastatic
prostate cancer receiving docetaxel with increased lean
body mass [20].
The findings highlighted a lack of clarity over the
origin of the muscle wastage and subsequently how it
may be assessed and treated, where generally the HCPs
spoke of a subjective assessment “by eye”. Given that a
side-effect of ADT includes central and visceral obesity;
such subjective assessments are likely to be misleading
[40]. This poses a significant risk specific to these men
where long term ADT is likely to mask any underlying
muscle wasting pathology. Equally, symptoms of muscle
wastage are very generalizable and can be difficult to
distinguish from that of other treatment-related side
effects (e.g. fatigue, impaired immune function and
metabolic abnormalities) [39]. Research must focus on
accurate and objective diagnostic measures of muscle
wastage to enable its successful treatment, improving
both the physiological wellbeing of these men and subse-
quently their response to cancer therapies.
There was an overwhelming view amongst HCPs that
currently very little is offered in the way of treatment to
address muscle wastage. Generally, diet and exercise
advice was offered for a majority of muscle wastage seen
in the clinic. Success from this approach was viewed as
variable and may be in part due to a lack of consistency
from HCP to HCP in the subjective nature of general
“exercise and diet advice” and the “one size fits all”
approach.
Compromising treatment was also mentioned by some
of the HCPs. Cessation of ADT or restricting the use of
steroids may be the case for men where muscle wastage
is of a significant detriment to QoL at the potential cost
of a survival benefit.
The consensus amongst the HCPs was that exercise
presents as an effective therapy, improving both physio-
logical and psychological outcomes as well as a tool
aiding in the management of adverse-effects. Almost all
the HCPs seemed to have knowledge of the current
NICE recommendations however there was some confu-
sion as to why action had not been taken nationally to
implement them.
As described earlier, it is clear that maintaining or
improving the PS of a man through his prostate cancer
journey is critical to obtaining the best possible
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outcomes. This includes the potential alleviation of
adverse-effects of treatment and the maintenance of a
good QoL, where the two go hand in hand. There is
increasing evidence demonstrating that exercise may
represent a useful stand alone or combination therapy
for the treatment of cancer, improving physiological and
psychosocial outcomes [41]. In addition, specific benefi-
cial effects of exercise training for improving lean body
mass (LBM) are also well established [24, 42].
By improving physical fitness through exercise there is
potential to not only improving the chances of receiving,
but also better tolerating, the appropriate cancer treat-
ments. Studies investigating the effectiveness of resist-
ance and aerobic training in cancer populations have
demonstrated an increase in chemotherapy completion
rate and treatment toxicities [42–44].
Most of the HCPs felt that exercise should form a
fundamental part of healthcare throughout the prostate
cancer care pathway. Support should be offered from
the beginning of a patient’s journey with prostate cancer
and carried right to the end even where he may reach
the castrate resistant phase of the disease, although there
is a significant lack of data for such interventions in the
population.
It is important to acknowledge the limitations to this
study. This qualitative study did not seek to establish
generalizability of findings but sought to gain a deeper
insight into the views and opinions of a selected group
of HCPs regarding the prostate cancer care pathway.
The study has highlighted some critical issues facing
prostate cancer treatment and management within the
NHS. However it is acknowledged that testing these
findings among a wider population of HCPs would be is
warranted in order to test the generalizability of the
findings. As the majority of interviewees were urologists
and oncologists the data may be more biased to the
perspectives of this particular group of professionals.
Due to the nature of how these participants were
recruited into the study the authors acknowledge that a
self-selection bias may also exist as 63% (n = 49) of the
HCPs approached expressed an interest in the research
themes; the sampling of the participants in this study
failed to address the views of those who did not express
an interest. The thematic framework approach to ana-
lysing the data were used, although commonly used
in healthcare research; this form of analysis is more
inductive and therefore stays strongly informed by a
priori reasoning [45].
To our knowledge, this is the first qualitative study of
HCPs to have focused on second-line treatment sequen-
cing; changes to practice due to the STAMPEDE and
CHAARTED trial data; adverse-effects of prostate cancer
treatment including muscle wastage, compromising
treatment and finally prostate cancer and exercise, with
a focus to men with CRPC. This study has highlighted
the need to investigate further with a wider group of
HCPs as well as involving the views, opinions and expe-
riences of men with CRPC. Further observations are
needed to develop clarity in the current prostate cancer
care pathway, identifying weaknesses as we evolve and
refine how we treat prostate cancer. Efforts need to be
made to help expand the oncology workforce as the
demand for cancer care is ever increasing. This will help
enable clinicians to carry out consistent care but also
recognise the need to vary treatment regimens depend-
ant on a patient’s individual needs. This is particularly
the case for those with CRPC who may have remained
on ADT for a number of years and therefore experience
significant detrimental adverse-effects from treatment
including muscle wastage. In addition, this study has
highlighted a lack suitable exercise provision based on
the NICE recommendations. Future research should
focus on how this can be improved and particularly in
men with more advanced disease who have a higher
disease burden, where the current data for exercise in
this population lacks.
Conclusions
The prostate cancer care pathway, including the optimum
sequencing of drugs, is evolving and further work will be
needed to reassess and optimize this pathway in light of
its recent changes. The adverse-effects of prostate cancer
treatments have a significant detrimental effect to patient
QoL. Exercise may present as a useful stand alone or com-
bination therapy in both the alleviation of adverse-effects
of treatment but also of the tolerance to treatment,
particularly where programmes aim to increase LBM. In
addition, fully integrated exercise programmes may enable
these men to retain or improve their PS ensuring access
to all available treatment options. Such programmes
should be available throughout the prostate cancer care
pathway and more research is needed for those at more
advanced stages of disease, particularly in CRPC where
data are lacking. A highly functioning, refined prostate
cancer care pathway with integrated exercise programmes
will allow men to maximise the benefits of the many treat-
ments they may have but also live well during this period,
maintaining a good QoL.
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